Announcements Announcements 2023 Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development Continue Reading
Announcements Announcements 2023 Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program Continue Reading
Announcements Announcements 2022 Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy Continue Reading
Publications & Posters Publications & Posters - 2022 SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
Publications & Posters Publications & Posters - 2022 SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Announcements Announcements 2022 Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting Continue Reading
Announcements Announcements 2022 Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference Continue Reading
News News - 2022 Biomed start-up Hummingbird Bioscience opens new facility to boost its R&D work Continue Reading
